London
A breast cancer patient this week sued Britain’s National Health Service for refusing to give her a drug that could save her life. Elaine Barber, a 41-year-old mother of four, was told that prescribing Herceptin, a new drug that costs up to $50,000 a year per patient, was not “a cost-effective use of finite health resources.” Last month, though, a different patient was given the drug on the grounds that her status as a single mother of a disabled child rendered her case “exceptional.” In most E.U. countries, drugs are made available through public health systems as soon as they get an E.U. license. But in Britain, drugs must also undergo a cost-benefit analysis.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Quiz of The Week: 15 – 21 NovemberQuiz Have you been paying attention to The Week’s news?
-
Can the UK do more on climate change?Today's Big Question Labour has shown leadership in the face of fraying international consensus, but must show the public their green mission is ‘a net benefit, not a net cost’
-
The Week Unwrapped: Will US Catholics rebel against the Pope?Podcast Plus what are the ethics of freezing your late partner?
